Additional European Equity News

Amundi (AMUN FP) - Q1 2026 (EUR): Revenue 902mln (prev. 823mln Y/Y), Net Income 349mln (prev. 303mln Y/Y). (Amundi) 

Aena (AENA SM) - Q1 2026 (EUR): Revenue 1.48bln (exp. 1.41bln), EBITDA 661.1mln, +2.7% Y/Y, Net Income 329.4mln, +9.3% Y/Y, Net Debt 5.02bln. EBITDA margin 44.7%. (Aena)

Aston Martin Lagonda (AML LN) - Q1 2026 (GBP): Revenue 270.4mln (prev. 233.9mln Y/Y), Gross Profit 93.9mln (prev. 65.2mln Y/Y), Adj. EBITDA 23.2mln (prev. -4.4mln Y/Y), Adj. EBIT -56.9mln (prev. -64.5mln Y/Y), Operating Loss -8.9mln (prev. -67.3mln Y/Y), LBT -65.5mln (prev. -79.6mln Y/Y), Net Debt -1.459bln (prev. -1.267bln Y/Y). Gross margin 34.7% (prev. 27.9% Y/Y, +680bps), Adj. EBITDA margin 8.6% (prev. -1.9% Y/Y), FY 2026 guidance unchanged. (Aston Martin Lagonda)

AstraZeneca (AZN LN) - Q1 2026 (USD): Revenue 15.3bln (exp. 14.9bln), adj. EPS 2.58 (exp. 2.55). Confirms guidance for FY26. "...remain on track to achieve our ambition for 2030 and beyond." 2026 Guidance (reconfirmed). Total Revenue is expected to increase by a mid-to-high single-digit percentage Core EPS is expected to increase by a low double-digit percentage. (AstraZeneca) 

Carlsberg (CARLB DC) - Q1 2026 (DKK): Revenue 20.7bln (exp. 20.7bln), reported volume growth 35.1mln/HL, 5.3%. Confirms FY26 earnings guidance. (Carlsberg)

Fortum (FORTUM FH) - Q1 2026 (EUR): Revenue 1.99bln (exp. 1.97bln), Adj. EBIT 521mln (exp. 470mln). (Fortum) 

Frasers (FRAS LN) - Acquires ork Designer Outlet and East Midlands Designer Outlet; no terms. (Frasers) 

GSK (GSK LN) - Q1 2026 (GBP) Adj. EPS 46.5p (exp. 43.2p), Turnover 7.63bln (prev. 7.51bln Y/Y), Gross Profit 1.87bln (prev. 1.93bln Y/Y); reaffirms 2026 guidance Others: Speciality Medicines 3.2bln, Vaccines 2.1bln. Specialty Medicines +14% Y/Y; Respiratory, Immunology & Inflammation 0.9bln (+16%), Oncology 0.5bln (+28%), HIV 1.8bln (+10%). Vaccines +4% Y/Y; Shingrix 1.0bln (+20%), Meningitis vaccines 0.3bln (-3%), Arexvy 0.1bln (-18%). Dividend: Q1 2026 dividend of 17p declared; 70p expected for full year 2026. GBP 1.7bln executed to date as part of the GBP 2bln share buyback programme announced at FY2024. Guidance: Expect 2026 turnover growth of between 3% to 5%; Core operating profit growth of between 7% to 9%; Core EPS growth of between 7% to 9%. 2031 sales outlook of more than GBP 40bln. (GSK)

Hikma (HIK LN) - Co. settles Pfizer (PFE) Vyndamax patent litigation. (Hikma) 

Haleon (HLN LN) - Q1 Trading Update, affirms outlook. (Haleon) 

Iberdrola (IBE SM) - Q1 2026 (EUR): Revenue 12bln (exp. 11.6bln), Net Income 1.71bln (prev. 2bln Y/Y), EBITDA 4.07bln (exp. 4.01bln). Solid first quarter and strong performance expected for the rest of the year. (Iberdrola) 

Jet2 (JET2 LN) - Trading Update: Op. Profit 435-440mln (prev. 446mln Y/Y). On sale capacity for Summer 2026 is currently 7.7% higher than Summer 2025, at 19.9m seats. Booked to date passengers are up by 6.2% with both package holidays and flight-only showing positive growth. Since commencement of the conflict in the Middle East, the booking profile has become increasingly close to departure. (Jet2) 

Lloyds (LLOY LN) - Q1 2026 (GBP): Statutory Pretax Profit 2.03bln (exp. 1.78bln), NII 3.56bln (prev. 3.29bln Y/Y), EPS 2.4p (prev. 1.7p Y/Y); reiterated guidance Guidance: "We are confident in our delivery for the year ahead and reiterate our guidance for 2026. We look forward to presenting our new strategy alongside the half-year results". Impairment: The underlying impairment charge was GBP 295mln (prev. GBP 309mln Y/Y), resulting in an asset quality ratio of 25 basis points. The MES charge reflects a £151 million impact from the deterioration in economic outlook as a result of the Middle East conflict. (Lloyds) 

Melrose Industries (MRO LN) - Q1 2026 (GBP): Revenue growth +11% Y/Y, Engines revenue growth +20% Y/Y, Airframes revenue growth +4% Y/Y. Adjusted operating profit ahead Y/Y with margin progression, net debt and free cash flow in line with expectations, FY 2026 guidance unchanged. (Melrose Industries)

Neste (NESTE FH) - Q1 2026 (EUR): Comparable EBITDA 861mln (exp. 758mln). (Neste) 

Teleperformance (TEP FP) - FY25 (EUR): Revenue 2.43bln (exp. 2.46bln), LFL -2.2% Y/Y. Affirms guidance (Teleperformance) 

TotalEnergies (TTE FP) - Q1 2026 (USD): adj. Net 5.39bln (exp. 4.98bln), Cash Flow 8.6bln (prev. 7.2bln Q/Q), Net income 5.8bln (prev. 2.9bln Q/Q), adj. EBITDA 12.6bln (prev. 10.1bln Q/Q). To continue buybacks. Outlook: Given the time required to restart production facilities in the Middle East (2-3 months), prices should remain at high levels during the second quarter. Competition between LNG demand in Europe to replenish storage and in Asia for the warm season should support prices in the coming months. (TotalEnergies) 

TRATON (8TRA GY) - Q1 2026 (EUR): Revenue 10.2bln (prev. 10.6bln Y/Y), Adj. EBIT 582mln (prev. 646mln Y/Y), EBIT 60mln (prev. 651mln Y/Y). Adj. operating margin 5.7% (prev. 6.1% Y/Y, -40bps), incoming orders +18% Y/Y, unit sales -6% Y/Y, FY outlook confirmed. (TRATON)

Worldline (WLN FP) - Q1 2026 (EUR): Revenue 831mln (prev. 1.07bln Y/Y). Co. to initiate a 40-1 reverse stock split. Affirms guidance. (Worldline) 

VAT Group (VACN LN) upgraded to Buy from Neutral by Goldman Sachs